Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2266-2273

  Drusano, G L ^a   Liu, Weiguo ^a   Fregeau, Christine ^a   Kulawy, Robert ^a   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MEROPENEM; MUTANT PROTEIN; PROTEIN MEXAB; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATE; CELL KILLING; DRUG POTENTIATION; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; WILD TYPE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; TOBRAMYCIN;

EID: 67049107918     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01680-08     Document Type: Article

References (9)

1. Calandra, G., F. Ricci, C. Wang, and K. Brown. 1986. Cross-resistance and imipenem. Lancet ii:340-341.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. CLSI publication M7-A7. Clinical and Laboratory Standards Institute Wayne, PA.
3. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles. http://bmsr.usc.edu/.
4. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siami, R. L. Zameck, D. C. Haverstock, H. H. Reinhart, R. M. Echols, and the Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
5. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
6. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
7. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203-216.
8. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
9. Tam, V. H., A. Louie, T. R. Fritsche, M. Deziel, W. Liu, D. L. Brown, L. Deshpande, R. Leary, R. N. Jones, and G. L. Drusano. 2007. Drug exposure intensity and duration of therapy's impact on emergence of resistance of Staphylococcus aureus to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.